CHOLETIMB 10 MG 14 TAB

* Indications:
  # Primary Hypercholesterolemia:
  – Choletimb, administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total-C,
  LDL-C and Apo B in patients with primary (heterozygous familial and non-familial) hypercholesterolemia.
  – Choletimb therapy with HMG-CoA reductase inhibitors: Choletimb, administered in combination with an HMG-CoA
  reductase inhibitor, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and
  Apo B in patients with primary (heterozygous familial and non-familial) hypercholesterolemia.
  – Also Choletimb reduces TG and increases HDL-C in patients with hypercholesterolemia.
  # Homozygous Familial Hypercholesterolemia (HoFH): The combination of Choletimb and statins, is indicated
  for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering
  treatments (e.g., LDL apheresis) or if such treatments are unavailable.
  # Homozygous Sitosterolemia: Choletimb is indicated as adjunctive therapy to diet for the reduction of elevated
  sitosterol & campesterol levels in patients with homozygous familial sitosterolemia.
  . Prior to initiating therapy with Choletimb, secondary causes for dyslipidemias (i.e. diabetes, hypothyroidism,
  obstructive liver disease, chronic renal failure, and drugs that increase LDL-C and decrease HDL-C
  [progestins, anabolic steroids, and corticosteroids]), should be excluded or, if appropriate, treated.
* Dosage and Administration:
  – The patient should be on an appropriate lipid-lowering diet before receiving Choletimb and should continue on
  this diet during treatment with Choletimb.
  – The recommended dose of Choletimb is 10mg once daily.
  – Choletimb can be administered with or without food.
  – Choletimb can be administered with an HMG-CoA reductase inhibitor for incremental effect. For convenience,
  the daily dose of Choletimb may be taken at the same time as the HMG-CoA inhibitor, according to the dosing
  recommendations for the HMG-CoA reductase inhibitor.
  – Patients with Hepatic Insufficiency: No dosage adjustment is necessary in patients with mild hepatic insufficiency.
  – Patients with Renal Insufficiency: No dosage adjustment is necessary in patients with renal insufficiency.
  – Geriatric Patients: No dosage adjustment is necessary in geriatric patients.
* Contraindications:
  – Hypersensitivity to any component of this medication.
  – The combination of Choletimb with an HMG-CoA reductase inhibitor is contraindicated in patients with active
  liver disease or unexplained persistent elevations of serum transaminases.
* Store at room temperature. Protect from moisture.
* Manufactured by: Marcyrl Pharmaceutical industries – Egypt.